BIOMAT Database Logo BIOMAT Database Logo

Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience. 2002

Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Pacific Oaks Medical Center, Beverly Hills, California 90211, USA.

A post hoc analysis of safety data from study protocol NZT40012 assessed the incidence of conditions defined by the Centers for Disease Control and Prevention in 86 zidovudine-naïve, antiretroviral-experienced patients with HIV-1 infection who responded poorly (plasma HIV-1 RNA > 1000 copies/mL) despite at least 4 months' treatment with stavudine-containing regimens. Peripheral neuropathy occurred in 21%; other conditions were seen less frequently (candidiasis [13%], herpes zoster [12%], diarrhea lasting > 1 month [9%], Pneumocystis carinii pneumonia [9%], and wasting syndrome [8%]). The incidence of peripheral neuropathy rose significantly with the number of drugs comprising treatment regimens (> or = 4 vs 1-3; P = .013) and tended to be higher in patients with longer exposure to stavudine (29% with > or = 24 months' exposure vs 13% with < 24 months). Because peripheral neuropathy was observed with such high frequency, vigilance for signs and symptoms of this condition appears warranted if stavudine-containing regimens are to be continued.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.
April 2001, HIV medicine,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
June 2012, Journal of neurovirology,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
August 2010, The Cochrane database of systematic reviews,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).
July 2002, AIDS research and human retroviruses,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy.
April 2013, Pain,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
January 2014, Antiviral therapy,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
January 2004, The Journal of antimicrobial chemotherapy,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Peripheral neuropathy and antiretroviral drugs.
March 2001, Journal of the peripheral nervous system : JPNS,
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.
March 2000, Journal of acquired immune deficiency syndromes (1999),
Anthony Scarsella, and Gregg Coodley, and Peter Shalit, and Roger Anderson, and Robin L Fisher, and Qiming Liao, and Lisa L Ross, and Jaime E Hernandez
Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.
April 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!